1 citations
,
April 2025 in “Journal of Clinical Medicine” Hair loss in alopecia areata can negatively affect sexual quality of life.
1 citations
,
June 2023 in “Journal of Dermatology” People with Alopecia Areata are more likely to have autoimmune diseases, inflammatory diseases, and mental health issues like anxiety and depression.
1 citations
,
January 2022 in “Springer eBooks” 1 citations
,
September 2021 in “Frontiers in Endocrinology” Minoxidil can help transgender males grow facial hair before starting testosterone therapy.
1 citations
,
December 2015 in “Vestnik dermatologii i venerologii” Patients with non-scarring alopecia often experience emotional disorders like depression and stress.
March 2026 in “Biomedicines” Antera 3D® offers more precise and detailed scar assessment than traditional methods.
January 2026 in “International Journal of Innovative Technologies in Social Science” Isotretinoin effectively treats severe acne but can cause various side effects, with the most serious being birth defects, requiring careful monitoring and contraception.
January 2026 in “Nature Reviews Urology” December 2025 in “PLOS Global Public Health” Women with PCOS in Bangladesh face significant mental health issues, especially in rural areas.
December 2025 in “Cosmetics” New treatments for alopecia show promise in restoring hair growth by targeting immune and hormonal factors.
November 2025 in “Journal of Cosmetic Dermatology” Saw palmetto extract safely improves hair growth and reduces hair loss.
November 2025 in “Frontiers in Psychiatry” People with androgenetic alopecia often experience more anxiety, depression, and lower self-esteem.
October 2025 in “Nature Reviews Disease Primers”
August 2025 in “Journal of Cosmetic Dermatology” Interest in new and personalized treatments for hair loss is growing.
Female pattern hair loss and polycystic ovary syndrome are often linked.
August 2025 in “Annals of Indian Psychiatry” Hair loss can affect mood, self-esteem, body image, and quality of life.
August 2025 in “Australasian Journal of Dermatology” Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.
July 2025 in “International Journal of Trichology” Ethical standards are crucial in cosmetic medicine to maintain integrity.
June 2025 in “Pharmaceutics” Ethosomes with 30% ethanol effectively deliver dutasteride to hair follicles for treating hair loss.
March 2025 in “Scientific Reports” Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.
March 2025 in “Journal of Education Health and Sport” Finasteride can cause sexual and psychological side effects, but these usually reverse after stopping the medication.
March 2025 in “International Journal of Trichology” Gloriosa superba poisoning can cause sudden hair loss, but hair usually regrows fully.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
January 2025 in “The World Journal of Men s Health” Finasteride temporarily suppresses brain activity, but some effects last even after stopping.
December 2024 in “Nutrients” Skin, hair, and nail changes can help detect eating disorders early.
November 2024 in “Clinical Cosmetic and Investigational Dermatology” Rosemary oil may effectively treat hair loss with fewer side effects, but more research is needed.
October 2024 in “Journal of the Endocrine Society” Metastatic cervical cancer can cause rare, severe Cushing's syndrome with high risk of death.
October 2024 in “Journal of the Endocrine Society” ACTH-dependent Cushing's syndrome linked to metastatic cervical cancer is rare and has high risks.
January 2024 in “JEADV clinical practice” Gender-affirming dermatology treatments generally improve mental well-being for transgender individuals, but more research is needed.
July 2023 in “The Journal of Clinical Endocrinology and Metabolism” Gender-affirming hormone therapy improves physical performance in trans men to the level of cisgender men, while in trans women, it increases fat mass and decreases muscle mass, with no advantage in physical performance after 2 years.